JP7538044B2 - 間葉系間質細胞エキソソームおよびそれらの使用 - Google Patents

間葉系間質細胞エキソソームおよびそれらの使用 Download PDF

Info

Publication number
JP7538044B2
JP7538044B2 JP2020560991A JP2020560991A JP7538044B2 JP 7538044 B2 JP7538044 B2 JP 7538044B2 JP 2020560991 A JP2020560991 A JP 2020560991A JP 2020560991 A JP2020560991 A JP 2020560991A JP 7538044 B2 JP7538044 B2 JP 7538044B2
Authority
JP
Japan
Prior art keywords
subject
thymic
exosomes
msc
species
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020560991A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523106A (ja
JP2021523106A5 (https=
Inventor
コーレンバナス，ステラ
ミチアリス，エス．，アレクサンダー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Publication of JP2021523106A publication Critical patent/JP2021523106A/ja
Publication of JP2021523106A5 publication Critical patent/JP2021523106A5/ja
Priority to JP2024033810A priority Critical patent/JP2024138218A/ja
Application granted granted Critical
Publication of JP7538044B2 publication Critical patent/JP7538044B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020560991A 2018-04-30 2019-04-26 間葉系間質細胞エキソソームおよびそれらの使用 Active JP7538044B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024033810A JP2024138218A (ja) 2018-04-30 2024-03-06 間葉系間質細胞エキソソームおよびそれらの使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862664696P 2018-04-30 2018-04-30
US62/664,696 2018-04-30
PCT/US2019/029275 WO2019217091A1 (en) 2018-04-30 2019-04-26 Mesenchymal stromal cell exosomes and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024033810A Division JP2024138218A (ja) 2018-04-30 2024-03-06 間葉系間質細胞エキソソームおよびそれらの使用

Publications (3)

Publication Number Publication Date
JP2021523106A JP2021523106A (ja) 2021-09-02
JP2021523106A5 JP2021523106A5 (https=) 2022-05-10
JP7538044B2 true JP7538044B2 (ja) 2024-08-21

Family

ID=68466806

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020560991A Active JP7538044B2 (ja) 2018-04-30 2019-04-26 間葉系間質細胞エキソソームおよびそれらの使用
JP2024033810A Pending JP2024138218A (ja) 2018-04-30 2024-03-06 間葉系間質細胞エキソソームおよびそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024033810A Pending JP2024138218A (ja) 2018-04-30 2024-03-06 間葉系間質細胞エキソソームおよびそれらの使用

Country Status (6)

Country Link
US (1) US12521418B2 (https=)
EP (1) EP3810271A4 (https=)
JP (2) JP7538044B2 (https=)
CN (1) CN112334190B (https=)
CA (1) CA3098514A1 (https=)
WO (1) WO2019217091A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3145493T3 (da) 2014-05-18 2022-10-31 Childrens Medical Center Fremgangsmåder og sammensætninger vedrørende exosomer
EP3801028A4 (en) 2018-05-30 2022-04-13 Direct Biologics LLC A growth factor and extracellular vesicle frozen or powdered additive comprising a mesenchymal stem cell (msc) preparation and methods of use
US12569517B2 (en) 2019-02-07 2026-03-10 Direct Biologics, Llc Method for treating osteoarthritis with mesenchymal stem cell exosomes
US12213995B2 (en) 2019-07-18 2025-02-04 Direct Biologics, Llc Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use
CN111281889A (zh) * 2020-04-16 2020-06-16 博生众康(厦门)医药生物技术股份有限公司 人脐带间充质干细胞外泌体的用途
KR20230004709A (ko) * 2020-04-22 2023-01-06 다이렉트 바이오로직스 엘엘씨 감염성 질환과 연관된 염증성 병태를 치료하기 위한 방법 및 조성물
CN117363568B (zh) * 2023-12-04 2024-04-09 山东大学 一种脂肪间充质干细胞外泌体及其制备方法与应用
US12502407B2 (en) 2024-04-25 2025-12-23 Direct Biologics, Llc Treatment of fistula with bone marrow mesenchymal stem cell derived extracellular vesicles

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017517505A (ja) 2014-05-18 2017-06-29 チルドレンズ メディカル センター コーポレーション エキソソームに関連する方法および組成物
JP2017526723A (ja) 2013-09-16 2017-09-14 エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ 移植片対宿主病（ｇｖｈｄ）または表皮水疱症（ｅｂ）のエキソソームによる治療方法
WO2017218964A1 (en) 2016-06-17 2017-12-21 United Therapeutics Corporation Extracellular vesicles with enhanced potency

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
US20040214783A1 (en) 2002-05-08 2004-10-28 Terman David S. Compositions and methods for treatment of neoplastic disease
US8021847B2 (en) 2004-06-02 2011-09-20 Proxy Life Science Holdings, Inc. Microvesicle-based compositions and methods
US8337815B2 (en) 2004-12-23 2012-12-25 Discovery Laboratories, Inc. Pulmonary surfactant formulations
WO2006110582A1 (en) 2005-04-08 2006-10-19 Xcyte Therapies, Inc. Compositions and methods for the treatment of burns and sepsis
WO2008020815A1 (en) 2006-08-15 2008-02-21 Agency For Science, Technology And Research Mesenchymal stem cell conditioned medium
EP1937801A1 (en) 2005-09-02 2008-07-02 Agency for Science, Technology and Research Method of deriving mesenchymal stem cells
US20090274665A1 (en) 2006-04-27 2009-11-05 Cell Therapy Technologies, Inc. Stem Cells For Treating Lung Diseases
PT2578081E (pt) 2006-10-11 2016-06-17 Massachusetts Inst Technology Composições, métodos e dispositivos para o tratamento de doenças hepáticas
EP1944361A1 (en) 2007-01-11 2008-07-16 INSERM (Institut National de la Santé et de la Recherche Médicale) A method for expanding monocytes
AU2009203638C1 (en) 2008-01-04 2013-07-25 Lydac Neuroscience Limited Microvesicles
EP2254586B1 (en) 2008-02-22 2015-04-08 Agency For Science, Technology And Research (A*star) Mesenchymal stem cell particles
SG177467A1 (en) 2009-07-23 2012-02-28 Agency Science Tech & Res Pre-natal mesenchymal stem cells
WO2011053257A2 (en) 2009-11-02 2011-05-05 Agency For Science, Technology And Research (A*Star) Methods of monitoring cellular states
KR101189655B1 (ko) 2010-06-30 2012-10-11 성균관대학교산학협력단 줄기세포 배양액을 포함하는 폐질환 치료용 조성물
CN101890050B (zh) 2010-07-14 2012-07-04 江苏大学 脐带间质干细胞来源膜性囊泡及其应用
WO2012020308A2 (en) 2010-08-13 2012-02-16 The University Court Of The University Of Glasgow Cellular and molecular therapies
EP2678448A4 (en) 2011-02-22 2014-10-01 Caris Life Sciences Luxembourg Holdings S A R L CIRCULATING BIOMARKERS
US9901600B2 (en) 2011-03-11 2018-02-27 Children's Medical Center Corporation Methods and compositions relating to mesenchymal stem cell exosomes
JP2014519340A (ja) 2011-06-16 2014-08-14 カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス．アー．エール．エル． バイオマーカー組成物および方法
ITTO20111183A1 (it) 2011-12-21 2013-06-22 Univ Degli Studi Torino Mezzo condizionato ottenuto da cellule staminali mesenchimali placentari e suo uso nel trattamento terapeutico della preeclampsia
US9427450B2 (en) 2012-01-31 2016-08-30 Xon Cells, Inc. Therapeutic immune modulation by stem cell secreted exosomes
EP2833893B1 (en) 2012-04-03 2018-08-29 Reneuron Limited Stem cell microparticles
KR101399056B1 (ko) 2012-04-16 2014-05-27 연세대학교 산학협력단 줄기세포-유래 미세소포체를 유효성분으로 포함하는 신경질환 예방 또는 치료용 약제학적 조성물
US20130273011A1 (en) 2012-04-17 2013-10-17 Medistem, Inc. Stem cells and stem cell generated nanoparticles for treatment of inflammatory conditions and acute radiation syndrome
US20150125950A1 (en) 2012-05-18 2015-05-07 Agency For Science, Technology And Research (A*Sta (A*Star) Umbilical cord mesenchymal stem cell exosomes
EP2687219A1 (en) 2012-07-18 2014-01-22 Universität Duisburg-Essen Use of preparations comprising exosomes derived from mesenchymal stem cells (MSCs) in the prevention and therapy of inflammatory conditions
JP2015524849A (ja) 2012-08-15 2015-08-27 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 神経変性疾患に対するエキソソームに基づく治療法
CN103767985A (zh) 2012-10-22 2014-05-07 吉林省霍普金斯药物研究院有限责任公司 人源血液或间充质干细胞分泌exosome的制备与应用
US20160002597A1 (en) 2013-02-12 2016-01-07 Reneuron Limited Method of producing microparticles
CA2910802A1 (en) 2013-04-12 2014-10-16 Samir El Andaloussi Therapeutic delivery vesicles
JP2016528151A (ja) 2013-08-07 2016-09-15 ピーアイ セラミック ゲーエムベーハー 鉛含有量が低減された圧電セラミック材料
WO2016043654A1 (en) 2014-09-15 2016-03-24 Agency For Science, Technology And Research Methods of treating graft versus host disease (gvhd) or epidermolysis bullosa (eb) with exosomes
US20180273906A1 (en) * 2014-04-17 2018-09-27 Muhammad Ashraf Microvesicle and stem cell compositions for therapeutic applications
US10166254B2 (en) 2014-09-19 2019-01-01 Wisconsin Alumni Research Foundation Use of mesenchymal stem cell-educated macrophages to treat and prevent graft versus host disease and radiation-induced injury
AU2017220148A1 (en) * 2016-02-18 2018-07-19 Pluristem Ltd. Methods and compositions for treating cancers and neoplasms
CN105769916B (zh) 2016-04-29 2019-07-23 南京大学 间充质干细胞来源外泌体在制备治疗子痫前期药物或者制剂中的应用
KR101973284B1 (ko) * 2017-01-16 2019-04-29 사회복지법인 삼성생명공익재단 신생아 ｈｉｅ 치료용 조성물
US11760975B2 (en) 2017-03-31 2023-09-19 Wisconsin Alumi Research Foundation Generation of therapeutic cells using extracellular components of target organs
CN111212653A (zh) 2017-08-15 2020-05-29 儿童医学中心公司 经纯化间充质干细胞外排体及其用途
US11499730B2 (en) 2018-02-12 2022-11-15 Wisconsin Alumni Research Foundation LPS priming of stromal cells to generate LPS-specific exosome educated macrophages
CA3099042A1 (en) 2018-05-09 2019-11-14 Children's Medical Center Corporation Mesenchymal stromal cell exosome -treated monocytes and uses thereof
EP3846782A4 (en) 2018-09-05 2022-07-13 Children's Medical Center Corporation Use of mesenchymal stromal cell exosomes in antenatal therapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017526723A (ja) 2013-09-16 2017-09-14 エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ 移植片対宿主病（ｇｖｈｄ）または表皮水疱症（ｅｂ）のエキソソームによる治療方法
JP2017517505A (ja) 2014-05-18 2017-06-29 チルドレンズ メディカル センター コーポレーション エキソソームに関連する方法および組成物
WO2017218964A1 (en) 2016-06-17 2017-12-21 United Therapeutics Corporation Extracellular vesicles with enhanced potency

Also Published As

Publication number Publication date
WO2019217091A1 (en) 2019-11-14
EP3810271A1 (en) 2021-04-28
CN112334190B (zh) 2024-09-20
CN112334190A (zh) 2021-02-05
US20210137989A1 (en) 2021-05-13
JP2021523106A (ja) 2021-09-02
US12521418B2 (en) 2026-01-13
CA3098514A1 (en) 2019-11-14
EP3810271A4 (en) 2022-01-26
JP2024138218A (ja) 2024-10-08

Similar Documents

Publication Publication Date Title
JP7538044B2 (ja) 間葉系間質細胞エキソソームおよびそれらの使用
KR101974842B1 (ko) 중간엽 줄기 세포의 용도
EP3027738B1 (en) Mscs in the treatment of inflammatory pulmonary diseases
Tokalov et al. Age-related changes in the frequency of mesenchymal stem cells in the bone marrow of rats
US20200289558A1 (en) Autologous and allogenic macrophages and monocytes for use in therapeutic methods
US20250170183A1 (en) Method for enriching muse cells and obtaining exosomes, microvesicles or the secretome therefrom
JP2024103800A (ja) 歯髄由来細胞の製造方法
KR102184722B1 (ko) 성체줄기세포 유래의 나노베시클 및 이의 표적 치료용 용도
US20170009208A1 (en) Biophysically Sorted Osteoprogenitors From Culture Expanded Bone Marrow Derived Mesenchymal Stromal Cells (MSCs)
JP2024163978A (ja) 間葉系間質細胞エキソソーム処置単球およびそれらの使用
Abedi et al. Robust conversion of marrow cells to skeletal muscle with formation of marrow-derived muscle cell colonies: a multifactorial process
BR112017014361B1 (pt) Uso de uma população de células-tronco mesenquimais (MSCS) modificadas com fucosiltransferase VI (FTVI) que expressa o ligante de E-L Selectina de célula hematopoiética (HCELL) para tratar diabetes
KR20220152240A (ko) 염증성 장 질환 ii의 치료 방법
US20230293589A1 (en) Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells
CN115361957A (zh) 治疗炎症性肠病的方法i
Class et al. Patent application title: MESENCHYMAL STROMAL CELL EXOSOMES AND USES THEREOF
Li et al. Modulating the phenotype and function of bone marrow-derived macrophages via mandible and femur osteoblasts
Abedi et al. Critical variables in the conversion of marrow cells to skeletal muscle
Park et al. Co-transplantation of human mesenchymal stem cells promotes human CD34+ cells engraftment in a dose-dependent fashion in NOD/SCID mice
KR101503020B1 (ko) 뉴로펩티드 y를 유효성분으로 포함하는 골다공증의 예방 또는 치료용 약학적 조성물
WO2026096838A1 (en) Treatment of organ dysfunction using a combination of mesenchymal stem cells and exosomes
CN118697899A (zh) 一种靶向脂肪细胞治疗骨质疏松症的纳米酶的制备方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220426

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220426

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230313

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230613

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230814

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240306

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240306

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240514

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240716

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240808

R150 Certificate of patent or registration of utility model

Ref document number: 7538044

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150